TORONTO, May 14, 2014 (GLOBE NEWSWIRE) -- GeneNews Limited (TSX:GEN) ("GeneNews") announces that all of the nominees listed in the management information circular for the annual meeting of shareholders held on Wednesday, May 14, 2014 were elected as directors of GeneNews.
Detailed results of the vote for the election of directors are set out below.
|Nominees||Votes FOR||% FOR||Votes WITHHELD||% WITHHELD|
|Floyd C. Dent III||19,976,797||99.99||1,000||0.01%|
GeneNews is a company focused on developing and commercializing proprietary molecular diagnostic tests for the early detection of diseases and personalized health management, with a primary focus on cancer-related indications. GeneNews' first product, ColonSentry®, is the world's first blood test to assess an individual's current risk for colorectal cancer. GeneNews' common shares trade on the Toronto Stock Exchange under the symbol 'GEN'. More information on GeneNews, can be found at www.GeneNews.com.
CONTACT: Company Contact: James R. Howard-Tripp Executive Chairman Office: (905) 739-2030 firstname.lastname@example.org Investor & Media Contact: Stephen Kilmer Kilmer Lucas Inc. Office: (212) 618-6347 Mobile: (905) 906-6908 email@example.comSource:GeneNews Limited